



## **Crescendo Biologics partners with software-provider, Genedata, on next-generation immuno-oncology and ADC programs**

**Cambridge, UK, 10 January 2017** – Crescendo Biologics Limited (Crescendo), the drug developer of Humabody® therapeutics, today announces it will use, Genedata’s workflow platform, Genedata Biologics™. The platform will be used for both Crescendo’s internal and its partnered Humabody®-based therapeutics programs, with the aim of increasing throughput and efficiency in discovery and development.

The Genedata Biologics software will streamline and accelerate Crescendo’s R&D programs, which are based on a novel class of small, robust protein therapeutics comprising fully human single V<sub>H</sub> domain building blocks (Humabody® V<sub>H</sub>). The Humabody® building blocks can be readily configured into an almost limitless number of multi-functional constructs which optimally engage therapeutically valuable targets. Crescendo will use Genedata Biologics to facilitate the swift identification and tracking of potential drug candidates with superior potency and developability.

“Due to the complexity and scale of our product design activities and the vast amounts of data generated during candidate testing, we needed to implement a scalable system to work as a backbone for all our R&D activities,” said **Dr. Thomas Sandal, VP R&D at Crescendo Biologics**. “Thanks to its flexible architecture, Genedata Biologics can truly support our entire discovery process – right through from the immunization of transgenic mice, to lead selection, molecular modification and final candidate assessments.”

“Companies with cutting-edge R&D technologies like Crescendo Biologics are important partners as we continue to develop and expand Genedata Biologics to keep pace with the latest scientific advances.” said **Dr. Othmar Pfannes, CEO of Genedata**.

**Ends**

**For more information, please contact:**

<b>Crescendo Biologics</b> <b>Dr Peter Pack, CEO</b>	<b>Tel:44 (0)1223 497140</b> <b>info@crescendobiologics.com</b>
<b>Instinctif Partners</b> <b>Dr Christelle Kerouedan / Melanie Toyne-Sewell</b>	<b>Tel:44 (0)20 7457 2020</b> <b>crescendo@instinctif.com</b>

**Notes to Editors:**



## **About Crescendo Biologics Ltd**

Crescendo Biologics is a biopharmaceutical company discovering and developing potent, highly differentiated mono- and multi-specific Humabody<sup>®</sup> therapeutics in oncology. The Company's Humabody<sup>®</sup> therapeutics are based on its unique, patent protected, transgenic mouse platform generating 100% human V<sub>H</sub> domain building blocks (Humabody<sup>®</sup> V<sub>H</sub>) with superior biophysical properties.

Crescendo is pursuing novel Humabody<sup>®</sup>-based product opportunities, through in-house development and strategic partnerships in both multi-specific immuno-oncology modulators and HDCs (Humabody<sup>®</sup> Drug Conjugates), the next generation of ADCs.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations) and Takeda.

For more information, please visit the website: [www.crescendobiologics.com](http://www.crescendobiologics.com) .

## **About Humabody<sup>®</sup> Therapeutics**

Humabodies are a novel class of extremely small, robust and potent protein therapeutics. They are based on fully human V<sub>H</sub> domain building blocks (Humabody<sup>®</sup> V<sub>H</sub>) isolated from heavy chain-only antibodies produced using Crescendo's proprietary transgenic mouse.

Compared with monoclonal antibodies, Humabodies offer a unique combination of potential benefits that results from their small size, cost-effective production and robust biophysical properties, allowing Crescendo to rapidly assemble and optimally configure an almost limitless range of Humabody formats.

Crescendo is developing a pipeline of novel, Humabody<sup>®</sup>-based therapeutics in oncology. HDCs (Humabody<sup>®</sup> Drug Conjugates) will deliver a superior therapeutic index to standard ADCs. Next-generation mono- and multi-specific Humabody<sup>®</sup> IO modulators are optimally configured for targeting a range of key mechanisms in the cancer immunity cycle. These include blocking inhibitory signals or activating stimulatory pathways of the immune response, as well as enhancing antigen presentation and inhibiting the immunosuppressive tumor microenvironment.

For more information, please visit the website: [www.crescendobiologics.com](http://www.crescendobiologics.com) .

## **About Genedata**

Genedata transforms life science data into intelligence with a portfolio of advanced software solutions and scientific consulting. With award-winning platforms, combined with deep domain expertise, Genedata enables dramatic increases in productivity and quality of research, development, and production. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, Japan, and the US.

For more information, visit [www.genedata.com](http://www.genedata.com)